FI104233B1 - Menetelmä stabiilien, interleukiineja sisältävien rokotekoostumusten valmistamiseksi - Google Patents

Menetelmä stabiilien, interleukiineja sisältävien rokotekoostumusten valmistamiseksi

Info

Publication number
FI104233B1
FI104233B1 FI920132A FI920132A FI104233B1 FI 104233 B1 FI104233 B1 FI 104233B1 FI 920132 A FI920132 A FI 920132A FI 920132 A FI920132 A FI 920132A FI 104233 B1 FI104233 B1 FI 104233B1
Authority
FI
Finland
Prior art keywords
vaccine compositions
preparation
compositions containing
interleukins
interleukin
Prior art date
Application number
FI920132A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI104233B (fi
FI920132A0 (fi
Inventor
Subramonia Pillai
Garvin Bixler
Original Assignee
American Cyanamid Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Cyanamid Co filed Critical American Cyanamid Co
Publication of FI920132A0 publication Critical patent/FI920132A0/fi
Application granted granted Critical
Publication of FI104233B publication Critical patent/FI104233B/fi
Publication of FI104233B1 publication Critical patent/FI104233B1/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
FI920132A 1989-07-14 1992-01-13 Menetelmä stabiilien, interleukiineja sisältävien rokotekoostumusten valmistamiseksi FI104233B1 (fi)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US37974289A 1989-07-14 1989-07-14
US37974289 1989-07-14
US9003982 1990-07-16
PCT/US1990/003982 WO1991001143A1 (en) 1989-07-14 1990-07-16 Stable vaccine compositions containing interleukins

Publications (3)

Publication Number Publication Date
FI920132A0 FI920132A0 (fi) 1992-01-13
FI104233B FI104233B (fi) 1999-12-15
FI104233B1 true FI104233B1 (fi) 1999-12-15

Family

ID=23498494

Family Applications (1)

Application Number Title Priority Date Filing Date
FI920132A FI104233B1 (fi) 1989-07-14 1992-01-13 Menetelmä stabiilien, interleukiineja sisältävien rokotekoostumusten valmistamiseksi

Country Status (12)

Country Link
EP (1) EP0482076B1 (no)
JP (2) JP3485184B2 (no)
KR (1) KR0177179B1 (no)
AT (1) ATE121629T1 (no)
AU (1) AU648509B2 (no)
CA (1) CA2063587C (no)
DE (1) DE69018990T2 (no)
DK (1) DK0482076T3 (no)
ES (1) ES2075900T3 (no)
FI (1) FI104233B1 (no)
NO (1) NO301577B1 (no)
WO (1) WO1991001143A1 (no)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6406696B1 (en) 1989-10-27 2002-06-18 Tolerance Therapeutics, Inc. Methods of stimulating the immune system with anti-CD3 antibodies
DE69032484D1 (de) * 1989-10-27 1998-08-20 Arch Dev Corp Zusammensetzungen und deren verwendung zur förderung der immunopotentiation
GR1000881B (el) * 1990-08-06 1993-03-16 Praxis Biolog Inc Σταθερες συνθεσεις εμβολιου που περιεχουν ιντερλευκινες.
AU9161591A (en) * 1990-12-19 1992-07-22 Schering Corporation Use of il-4 to enhance immune response to immunogens in vaccines
WO1992020370A1 (en) * 1991-05-13 1992-11-26 Regents Of The University Of California Liposomal polysaccharide vaccines
DE4126983A1 (de) 1991-08-15 1993-02-18 Boehringer Mannheim Gmbh Verfahren zur herstellung von humanprotein-enthaltenden, konservierten arzneimitteln fuer infusions- oder injektionszwecke
DE69310182T2 (de) * 1992-08-10 1997-12-04 Us Gov Health & Human Serv Interleukin-4 stimulierter t-lymphozyten-zelltod
ZA936095B (en) * 1992-08-21 1994-03-14 Univ Melbourne Cytokine applications.
US6491916B1 (en) 1994-06-01 2002-12-10 Tolerance Therapeutics, Inc. Methods and materials for modulation of the immunosuppresive activity and toxicity of monoclonal antibodies
WO1996007102A1 (en) * 1994-09-01 1996-03-07 Wisconsin Alumni Research Foundation Therapeutic remodeling in aids
US6509313B1 (en) 1996-02-28 2003-01-21 Cornell Research Foundation, Inc. Stimulation of immune response with low doses of cytokines
AU724743B2 (en) * 1996-05-31 2000-09-28 Genetics Institute, Llc IL-12 as an adjuvant for Bordetella Pertussis vaccines
TW586934B (en) * 1997-05-19 2004-05-11 Sumitomo Pharma Immunopotentiating composition
US6270758B1 (en) 1998-10-08 2001-08-07 Duke University Substantially non-toxic biologically active mucosal adjuvants in vertebrate subjects
US6027731A (en) * 1998-11-17 2000-02-22 Wisconsin Alumni Research Foundation Pertussis toxin induced lymphocytosis
IT1302534B1 (it) 1998-12-21 2000-09-05 Fidia Advanced Biopolymers Srl Composizioni iniettabili, biocompatibili e biodegradabili comprendentialmeno un derivato dell'acido ialuronico, cellule condrogeniche, per
SK782002A3 (en) * 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
DE60040740D1 (de) 1999-12-03 2008-12-18 Celltech Chiroscience Ltd VERWENDUNG OF INTERLEUkIN-1 MUTEIN ALS IMPFSTOFFADJUVANS
EP2497496A3 (en) 2005-07-11 2013-02-20 Macrogenics, Inc. Methods for the treatment of autoimmune disorders using immunosuppressive monoclonal antibodies with reduced toxicity
JP2009510032A (ja) * 2005-09-30 2009-03-12 リポクセン テクノロジーズ リミテッド 多糖抗原及びタンパク質アジュバントを含む多価リポソームワクチン組成物
BRPI0713426A2 (pt) 2006-06-14 2012-10-09 Macrogenics Inc métodos de tratar, diminuir a progressão, ou melhorar um ou mais sintomas de um distúrbio, e de prevenir ou retardar o inìcio de um distúrbio
US7709010B2 (en) * 2007-03-09 2010-05-04 Merck Sharp & Dohme Corp. Papillomavirus vaccine compositions
ES2641375T3 (es) * 2012-11-02 2017-11-08 Cytuvax Composición que comprende macroagregados de citoquinas
JOP20190242A1 (ar) * 2018-10-12 2020-04-12 Serum Institute Of India Pvt Ltd تركيبة لقاح توليفي تشمل فيروس شلل الأطفال ذو جرعة مخفّضة خاملة التنشيط وطريقة لتحضيرها
CN113365650A (zh) 2018-11-16 2021-09-07 新免疫技术有限公司 用il-7蛋白和免疫检查点抑制剂的组合治疗肿瘤的方法
WO2021146191A1 (en) 2020-01-13 2021-07-22 Neoimmunetech, Inc. Method of treating a tumor with a combination of il-7 protein and a bispecific antibody
JP2023512657A (ja) 2020-02-05 2023-03-28 ワシントン・ユニバーシティ Ｉｌ－７タンパク質とｃａｒ保有免疫細胞の組み合わせで固形腫瘍を治療する方法
US20230398184A1 (en) 2020-10-26 2023-12-14 Neoimmunetech, Inc. Methods of inducing stem cell mobilization
KR20230104176A (ko) 2020-11-02 2023-07-07 네오이뮨텍, 인코퍼레이티드 코로나바이러스의 치료를 위한 인터류킨-7의 용도
AU2021376396A1 (en) 2020-11-05 2023-06-08 Neoimmunetech, Inc. Method of treating a tumor with a combination of an il-7 protein and a nucleotide vaccine
WO2023130081A1 (en) 2021-12-30 2023-07-06 Neoimmunetech, Inc. Method of treating a tumor with a combination of il-7 protein and vegf antagonist
WO2024102722A1 (en) 2022-11-07 2024-05-16 Neoimmunetech, Inc. Methods of treating a tumor with an unmethylated mgmt promoter

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2849632B2 (ja) * 1988-04-08 1999-01-20 社団法人北里研究所 ワクチン製剤
DE3818054C2 (de) * 1988-05-27 1994-02-17 Biotest Pharma Gmbh Verwendung einer Kombination aus einem Antigen bzw. einer Vakzine und humanem Interleukin zur Behandlung der Non-Responsiveness gegenüber immunologischen Defektzuständen
JPH0236129A (ja) * 1988-07-22 1990-02-06 Ajinomoto Co Inc ワクチン効果増強剤

Also Published As

Publication number Publication date
KR0177179B1 (ko) 1999-03-20
EP0482076B1 (en) 1995-04-26
AU6050090A (en) 1991-02-22
FI104233B (fi) 1999-12-15
JP2004002463A (ja) 2004-01-08
ATE121629T1 (de) 1995-05-15
KR920703103A (ko) 1992-12-17
DK0482076T3 (da) 1995-07-17
EP0482076A1 (en) 1992-04-29
NO920161D0 (no) 1992-01-13
JP3485184B2 (ja) 2004-01-13
JPH04506663A (ja) 1992-11-19
WO1991001143A1 (en) 1991-02-07
FI920132A0 (fi) 1992-01-13
AU648509B2 (en) 1994-04-28
ES2075900T3 (es) 1995-10-16
DE69018990D1 (de) 1995-06-01
NO920161L (no) 1992-03-05
DE69018990T2 (de) 1995-12-14
NO301577B1 (no) 1997-11-17
CA2063587A1 (en) 1991-01-15
CA2063587C (en) 2005-08-30

Similar Documents

Publication Publication Date Title
FI104233B1 (fi) Menetelmä stabiilien, interleukiineja sisältävien rokotekoostumusten valmistamiseksi
CA2231603A1 (en) Chicken interleukin-15 and uses thereof
GB2210557B (en) Vaccine containing tumor antigens and refined detoxified endotoxin as an adjuvant.
PT76502A (en) Process for the preparation of n-glycosylated carboxamide derivatives with s stimulating effect of the body's inherent defences and their application for the preparation of pharmaceutical compositions having a stimulating effect of body's inherent defences
GB8403921D0 (en) Preparation of lyophilized adsorbed polyvalent vaccines
NO971792D0 (no) Blanding inneholdende en aerogel, dens fremstilling og anvendelse
ES2092306T3 (es) Adyuvante para vacunas.
CA2103887A1 (en) Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
IT8322155A0 (it) Procedimento per immobilizzare materie biologiche e composto di materie biologiche adsorbite in vermiculite.
IT1164858B (it) Procedimento per la preparazione di vaccini a base di virus con proteine superficiali ricombinanti e prodotto ottenuto
FI851859L (fi) Antigenpreparat och isolering av saodana preparat.
NO924103L (no) Anvendelse av antistoffholdige preparater for immunundertrykkelse
NZ309659A (en) Composition comprising LbeIF4A and/or LmeIF4A polypeptides (Leishmania antigen) and methods for enhancing immune responses
DE69427824D1 (de) Impfstoffe bestehend aus protein- oder peptid-"cochleaten" und deren verwendung zur immunisierung
RU94040856A (ru) Вакцина для перорального введения
ATE275421T1 (de) Interleukin-12 und herpes simplex virusantigen enthaltende impfstoffe
EP0994721A4 (en) NERVOUS GROWTH FACTOR AS A VACCINE ADDITIVE
NZ189756A (en) Muramyl peptides antigens covalently bonded to muramyl-peptides medicaments and vaccines
ZA813479B (en) Process for the isolation of viral glycoproteic antigens and its application to the preparation of vaccines
AU8298991A (en) Antigenic iron repressible proteins from n. meningitidis related to the hemolysin family of toxins
EP0268640A4 (en) VACCINE STIMULATING OR IMPROVING THE PRODUCTION OF ANTIBODIES AGAINST GM2.
SE8404334L (sv) 16-fluoro-16,17-didehydro-prostanoider och forfarande for deras framstellning
ATE44651T1 (de) Immunogene protein- oder peptidkomplexe enthaltende vakzine.
AU5343390A (en) Preparation of unassembled pilus subunits and vaccines containing them
ZA807459B (en) Infectious bronchitis vaccines for poultry and process for the preparation of such vaccines

Legal Events

Date Code Title Description
GB Transfer or assigment of application

Owner name: AMERICAN CYANAMID COMPANY

MA Patent expired